Anixa Biosciences (NASDAQ:ANIX) Receives “Buy” Rating from D. Boral Capital

D. Boral Capital reaffirmed their buy rating on shares of Anixa Biosciences (NASDAQ:ANIX) in a report released on Monday morning,Benzinga reports. They currently have a $10.00 price objective on the stock.

Other analysts have also issued research reports about the stock. Wall Street Zen raised shares of Anixa Biosciences from a “sell” rating to a “hold” rating in a report on Friday, June 6th. HC Wainwright restated a “buy” rating and set a $7.00 price target on shares of Anixa Biosciences in a research report on Thursday, September 11th. Three analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of $9.00.

Anixa Biosciences Trading Up 5.8%

Anixa Biosciences stock opened at $3.49 on Monday. The business’s 50 day simple moving average is $3.13 and its 200 day simple moving average is $2.99. Anixa Biosciences has a 12 month low of $2.07 and a 12 month high of $4.20. The company has a market cap of $114.89 million, a price-to-earnings ratio of -9.97 and a beta of 0.58.

Anixa Biosciences (NASDAQ:ANIX) last announced its quarterly earnings data on Wednesday, September 10th. The company reported ($0.07) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.03. As a group, equities research analysts forecast that Anixa Biosciences will post -0.41 earnings per share for the current fiscal year.

Insider Activity

In other news, Director Lewis H. Titterton, Jr. purchased 10,000 shares of the company’s stock in a transaction on Thursday, July 31st. The stock was acquired at an average price of $3.08 per share, with a total value of $30,800.00. Following the transaction, the director directly owned 953,334 shares of the company’s stock, valued at approximately $2,936,268.72. This represents a 1.06% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders have purchased a total of 35,000 shares of company stock valued at $110,700 in the last quarter. 25.30% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Anixa Biosciences

Large investors have recently made changes to their positions in the business. Millennium Management LLC bought a new position in Anixa Biosciences in the fourth quarter worth about $26,000. Jane Street Group LLC purchased a new position in shares of Anixa Biosciences during the 4th quarter worth approximately $67,000. Private Advisor Group LLC bought a new position in shares of Anixa Biosciences in the 1st quarter worth approximately $35,000. Marshall Wace LLP bought a new position in shares of Anixa Biosciences in the 2nd quarter worth approximately $39,000. Finally, Benjamin Edwards Inc. purchased a new position in shares of Anixa Biosciences in the 2nd quarter valued at approximately $37,000. 29.13% of the stock is currently owned by institutional investors.

Anixa Biosciences Company Profile

Anixa Biosciences, Inc, a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer.